Gliomatosis cerebri: growing evidence for diffuse gliomas with wide invasion

References

• Nevin S. Gliomatosis cerebri. Brain61, 170–191 (1938).
   Google Scholar
• Scherer HJ. Cerebral astrocytomas and their derivatives. Am. J. Cancer40, 159–197 (1940).
   Google Scholar
• Scheinker IM, Evans JP. Diffuse cerebral glioblastosis. J. Neuropathol. Exp. Neurol.2, 78–189 (1943).
   Google Scholar
• Kawano N, Miyasaka Y, Yada K, Atari H, Sasaki K. Diffuse cerebrospinal gliomatosis. Case report. J. Neurosurg.49(2), 303–307 (1978).
   PubMed Web of Science ®Google Scholar
• Freund M, Hahnel S, Sommer C et al. CT and MRI findings in gliomatosis cerebri: a neuroradiologic and neuropathologic review of diffuse infiltrating brain neoplasms. Eur. Radiol.11(2), 309–316 (2001).
   PubMed Web of Science ®Google Scholar
• Fuller GN, Kros JM. Gliomatosis cerebri. In: WHO Classification of Tumours of the Central Nervous System. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds). IARC Press, Lyon, France, 50–52 (2007).
   Google Scholar
• Cummings TJ, Hulette CM, Longee DC et al. Gliomatosis cerebri: cytologic and autopsy findings in a case involving the entire neuraxis. Clin. Neuropathol.18(4), 190–197 (1999).
   PubMed Web of Science ®Google Scholar
• Mawrin C, Aumann V, Kirches E et al. Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide. J. Neurooncol.55(1), 11–17 (2001).
   PubMed Web of Science ®Google Scholar
• Zülch KJ. Histological Typing of Tumours of the Central Nervous System. World Health Organization, Geneva, Switzerland (1979).
   Google Scholar
• Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System. Springer, Berlin Heidelberg NY, USA (1993).
   Google Scholar
• Lantos PL, Bruner JM. Gliomatosis cerebri. In: Pathology and Genetics of Tumours of the Nervous System. Kleihues P, Cavenee WK (Eds). IARC Press, Lyon, France 92–93 (2000).
   Google Scholar
• Blumbergs PC, Chin DK, Hallpike JF. Diffuse infiltrating astrocytoma (gliomatosis cerebri) with twenty-two-year history. Clin. Exp. Neurol.19, 94–101 (1983).
   PubMedGoogle Scholar
• Barth PG, Stam FC, Hack W, Delemarre-van de Waal HA. Gliomatosis cerebri in a newborn. Neuropediatrics19(4), 197–200 (1988).
   PubMed Web of Science ®Google Scholar
• Jennings MT, Frenchman M, Shehab T et al. Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J. Child Neurol.10(1), 37–45 (1995).
   PubMed Web of Science ®Google Scholar
• Taillibert S, Chodkiewicz C, Laigle-Donadey F et al. Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J. Neurooncol.76(2), 201–205 (2006).
   PubMed Web of Science ®Google Scholar
• Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH. Gliomatosis cerebri: improved outcome with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.56(4), 1137–1146 (2003).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Izumoto S, Fujimoto Y et al. Clinicopathological study of cellular proliferation and invasion in gliomatosis cerebri: important role of neural cell adhesion molecule L1 in tumour invasion. J. Clin. Pathol.58(2), 166–171 (2005).
   PubMed Web of Science ®Google Scholar
• Li L, He F, Litofsky NS, Recht LD, Ross AH. Profiling of genes expressed by PTEN haploinsufficient neural precursor cells. Mol. Cell Neurosci.24(4), 1051–1061 (2003).
   PubMed Web of Science ®Google Scholar
• Galatioto S, Marafioti T, Cavallari V, Batolo D. Gliomatosis cerebri. Clinical, neuropathological, immunohistochemical and morphometric Studies. Zentralbl. Pathol.139(3), 261–267 (1993).
   PubMedGoogle Scholar
• Nishioka H, Ito H, Miki T. Difficulties in the antemortem diagnosis of gliomatosis cerebri: report of a case with diffuse increase of gemistocyte-like cells, mimicking reactive gliosis. Br. J. Neurosurg.10(1), 103–107 (1996).
   PubMed Web of Science ®Google Scholar
• Schober R, Mai JK, Volk B, Wechsler W. Gliomatosis cerebri: bioptical approach and neuropathological verification. Acta Neurochir. (Wien)113(3–4), 131–137 (1991).
   PubMed Web of Science ®Google Scholar
• Wilson NW, Symon L, Lantos PL. Gliomatosis cerebri: report of a case presenting as a focal cerebral mass. J. Neurol.234(6), 445–447 (1987).
   PubMed Web of Science ®Google Scholar
• Cervos-Navarro J, Artigas J, Aruffo C, Iglesias J. The fine structure of gliomatosis cerebri. Virchows Arch. A. Pathol. Anat. Histopathol.411(1), 93–98 (1987).
   PubMedGoogle Scholar
• Artigas J, Cervos-Navarro J, Iglesias JR, Ebhardt G. Gliomatosis cerebri: clinical and histological findings. Clin. Neuropathol.4(4), 135–148 (1985).
   PubMed Web of Science ®Google Scholar
• Balko MG, Blisard KS, Samaha FJ. Oligodendroglial gliomatosis cerebri. Hum. Pathol.23(6), 706–707 (1992).
   PubMed Web of Science ®Google Scholar
• Gutowski NJ, Gomez-Anson B, Torpey N et al. Oligodendroglial gliomatosis cerebri: (1)H-MRS suggests elevated glycine/inositol levels. Neuroradiology41(9), 650–653 (1999).
   PubMed Web of Science ®Google Scholar
• Tancredi A, Mangiola A, Guiducci A, Peciarolo A, Ottaviano P. Oligodendrocytic gliomatosis cerebri. Acta Neurochir. (Wien)142(4), 469–472 (2000).
   PubMed Web of Science ®Google Scholar
• Blümcke I, Muller S, Buslei R, Riederer BM, Wiestler OD. Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors. Acta Neuropathol. (Berl.)108(2), 89–96 (2004).
   PubMed Web of Science ®Google Scholar
• Mawrin C. Molecular genetic alterations in gliomatosis cerebri: what can we learn about the origin and course of the disease? Acta Neuropathol. (Berl.)110(6), 527–536 (2005).
   PubMed Web of Science ®Google Scholar
• Hulette CM. Microglioma, a histiocytic neoplasm of the central nervous system. Mod. Pathol.9(3), 316–319 (1996).
   PubMed Web of Science ®Google Scholar
• Watanabe K, Sato K, Biernat W et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res.3(4), 523–530 (1997).
   PubMed Web of Science ®Google Scholar
• Kannuki S, Hirose T, Horiguchi H, Kageji T, Nagahiro S. Gliomatosis cerebri with secondary glioblastoma formation: report of two cases. Brain Tumor Pathol.15(2), 111–116 (1998).
   PubMedGoogle Scholar
• Mawrin C, Lins H, Kirches E et al. Distribution of p53 alterations in a case of gliomatosis cerebri. Hum. Pathol.34(1), 102–106 (2003).
   PubMed Web of Science ®Google Scholar
• Pyhtinen J, Paakko E. A difficult diagnosis of gliomatosis cerebri. Neuroradiology38(5), 444–448 (1996).
   PubMed Web of Science ®Google Scholar
• Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol.1(1), 44–51 (1999).
   PubMedGoogle Scholar
• Kim DG, Yang HJ, Park IA et al. Gliomatosis cerebri: clinical features, treatment, and prognosis. Acta Neurochir. (Wien)140(8), 755–762 (1998).
   PubMed Web of Science ®Google Scholar
• Vates GE, Chang S, Lamborn KR, Prados M, Berger MS. Gliomatosis cerebri: a review of 22 cases. Neurosurgery53(2), 261–271 (2003).
   PubMed Web of Science ®Google Scholar
• Peretti-Viton P, Brunel H, Chinot O et al. Histological and MR correlations in gliomatosis cerebri. J. Neurooncol.59(3), 249–259 (2002).
   PubMed Web of Science ®Google Scholar
• Grossman SA, O’Neill A, Grunnet M et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J. Clin. Oncol.21(8), 1485–1491 (2003).
   PubMed Web of Science ®Google Scholar
• Buckner JC, O’Fallon JR, Dinapoli RP et al. Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. J. Neurooncol.84(3), 279–286 (2007).
   PubMed Web of Science ®Google Scholar
• Houillier C, Lejeune J, Benouaich-Amiel A et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer106(10), 2218–2223 (2006).
   PubMed Web of Science ®Google Scholar
• Akman F, Cooper RA, Sen M, Tanriver Y, Kentli S. Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: how useful are prognostic indices in routine clinical practice? J. Neurooncol.59(1), 39–47 (2002).
   PubMed Web of Science ®Google Scholar
• Polin RS, Marko NF, Ammerman MD et al. Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. J. Neurosurg.102(2), 276–283 (2005).
   PubMed Web of Science ®Google Scholar
• Jung V, Romeike BF, Henn W et al. Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. J. Neuropathol. Exp. Neurol.58(9), 993–999 (1999).
   PubMed Web of Science ®Google Scholar
• Loeper S, Romeike BF, Heckmann N et al. Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas. Cytogenet. Cell Genet.94(1–2), 1–8 (2001).
   PubMedGoogle Scholar
• Romeike BF, Jung V, Feiden W et al. Distribution of epidermal growth factor receptor protein correlates with gain in chromosome 7 revealed by comparative genomic hybridization after microdissection in glioblastoma multiforme. Pathol. Res. Pract.197(6), 427–431 (2001).
   PubMed Web of Science ®Google Scholar
• Yamada SM, Hayashi Y, Takahashi H et al. Histological and genetic diagnosis of gliomatosis cerebri: case report. J. Neurooncol.52(3), 237–240 (2001).
   PubMed Web of Science ®Google Scholar
• Hecht BK, Turc-Carel C, Chatel M et al. Chromosomes in gliomatosis cerebri. Genes Chromosomes Cancer14(2), 149–153 (1995).
   PubMed Web of Science ®Google Scholar
• Kattar MM, Kupsky WJ, Shimoyama RK et al. Clonal analysis of gliomas. Hum. Pathol.28(10), 1166–1179 (1997).
   PubMed Web of Science ®Google Scholar
• Kirches E, Mawrin C, Schneider-Stock R et al. Mitochondrial DNA as a clonal tumor cell marker: gliomatosis cerebri. J. Neurooncol.61(1), 1–5 (2003).
   PubMed Web of Science ®Google Scholar
• Kirches E, Michael M, Woy C et al. Loss of heteroplasmy in the displacement loop of brain mitochondrial DNA in astrocytic tumors. Genes Chromosomes Cancer26(1), 80–83 (1999).
   PubMed Web of Science ®Google Scholar
• Kirches E, Krause G, Warich-Kirches M et al. High frequency of mitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence comparison to blood samples. Int. J. Cancer93(4), 534–538 (2001).
   PubMed Web of Science ®Google Scholar
• Sanchez-Cespedes M, Parrella P, Nomoto S et al. Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res.61(19), 7015–7019 (2001).
   PubMed Web of Science ®Google Scholar
• Kros JM, Zheng P, Dinjens WN, Alers JC. Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis. J. Neuropathol. Exp. Neurol.61(9), 806–814 (2002).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Felsberg J, Küker W et al. Gliomatosis cerebri: molecular pathology and clinical course. Ann. Neurol.52, 390–399 (2002).
   PubMed Web of Science ®Google Scholar
• Sanson M, Cartalat-Carel S, Taillibert S et al. Initial chemotherapy in gliomatosis cerebri. Neurology63(2), 270–275 (2004).
   PubMed Web of Science ®Google Scholar
• von Deimling A, Eibl RH, Ohgaki H. p53 mutations are sssociated with 17p allelic loss in grade II and grade III astrocytomas. Cancer Res.52, 2987–2990 (1992).
   PubMed Web of Science ®Google Scholar
• Sidransky D, Mikkelsen T, Schwechheimer K et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature355(6363), 846–847 (1992).
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Eibl RH, Wiestler OD et al. p53 mutations in nonastrocytic human brain tumors. Cancer Res.51(22), 6202–6205 (1991).
   PubMed Web of Science ®Google Scholar
• Mawrin C, Kirches E, Schneider-Stock R et al. Analysis of TP53 and PTEN in gliomatosis cerebri. Acta Neuropathol. (Berl.)105(6), 529–536 (2003).
   PubMed Web of Science ®Google Scholar
• Mawrin C, Kirches E, Schneider-Stock R et al. Alterations of cell cycle regulators in gliomatosis cerebri. J. Neurooncol.72(2), 115–122 (2005).
   PubMed Web of Science ®Google Scholar
• Tohma Y, Gratas C, Biernat W et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol.57(7), 684–689 (1998).
   PubMed Web of Science ®Google Scholar
• von Deimling A, von Ammon K, Schoenfeld D et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol.3(1), 19–26 (1993).
   PubMed Web of Science ®Google Scholar
• Loda M, Cukor B, Tam SW et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med.3(2), 231–234 (1997).
   PubMed Web of Science ®Google Scholar
• Catzavelos C, Bhattacharya N, Ung YC et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med.3(2), 227–230 (1997).
   PubMed Web of Science ®Google Scholar
• Piva R, Cavalla P, Bortolotto S et al. p27/kip1 expression in human astrocytic gliomas. Neurosci. Lett.234(2–3), 127–130 (1997).
   PubMed Web of Science ®Google Scholar
• Asher R, Bignami A. Hyaluronate binding and CD44 expression in human glioblastoma cells and astrocytes. Exp. Cell Res.203(1), 80–90 (1992).
   PubMed Web of Science ®Google Scholar
• Ylagan LR, Quinn B. CD44 expression in astrocytic tumors. Mod. Pathol.10(12), 1239–1246 (1997).
   PubMed Web of Science ®Google Scholar
• Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J. Neurosurg.83(2), 298–307 (1995).
   PubMed Web of Science ®Google Scholar
• Oz B, Karayel FA, Gazio NL, Ozlen F, Balci K. The distribution of extracellular matrix proteins and CD44S expression in human astrocytomas. Pathol. Oncol. Res.6(2), 118–124 (2000).
   PubMedGoogle Scholar
• Leins A, Riva P, Lindstedt R et al. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer98(11), 2430–2439 (2003).
   PubMed Web of Science ®Google Scholar
• Burke D, Wilkes D, Blundell TL, Malcolm S. Fibroblast growth factor receptors: lessons from the genes. Trends Biochem. Sci.23(2), 59–62 (1998).
   PubMed Web of Science ®Google Scholar
• Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc. Natl Acad. Sci. USA91(2), 484–488 (1994).
   PubMed Web of Science ®Google Scholar
• Kunishio K, Okada M, Matsumoto Y, Nagao S. Matrix metalloproteinase-2 and -9 expression in astrocytic tumors. Brain Tumor Pathol.20(2), 39–45 (2003).
   PubMedGoogle Scholar
• Mawrin C, Schneider T, Firsching R et al. Assessment of tumor cell invasion factors in gliomatosis cerebri. J. Neurooncol.73(2), 109–115 (2005).
   PubMed Web of Science ®Google Scholar
• Ariza A, Lopez D, Mate JL et al. Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemistry study. Hum. Pathol.26(10), 1144–1147 (1995).
   PubMed Web of Science ®Google Scholar
• Kuppner MC, Van Meir E, Gauthier T, Hamou MF, de Tribolet N. Differential expression of the CD44 molecule in human brain tumours. Int. J. Cancer50(4), 572–577 (1992).
   PubMed Web of Science ®Google Scholar
• Nagasaka S, Tanabe KK, Bruner JM et al. Alternative RNA splicing of the hyaluronic acid receptor CD44 in the normal human brain and in brain tumors. J. Neurosurg.82(5), 858–863 (1995).
   PubMed Web of Science ®Google Scholar
• Bange J, Prechtl D, Cheburkin Y et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res.62(3), 840–847 (2002).
   PubMed Web of Science ®Google Scholar
• Streit S, Bange J, Fichtner A et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int. J. Cancer111(2), 213–217 (2004).
   PubMed Web of Science ®Google Scholar
• Jezequel P, Campion L, Joalland MP et al. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br. J. Cancer90(1), 189–193 (2004).
   PubMed Web of Science ®Google Scholar
• Karim AB, Maat B, Hatlevoll R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int. J. Radiat. Oncol. Biol. Phys.36(3), 549–556 (1996).
   PubMed Web of Science ®Google Scholar
• Horst E, Micke O, Romppainen ML et al. Radiation therapy approach in gliomatosis cerebri – case reports and literature review. Acta Oncol.39(6), 747–751 (2000).
   PubMed Web of Science ®Google Scholar
• Elshaikh MA, Stevens GH, Peereboom DM et al. Gliomatosis cerebri. Cancer95(9), 2027–2031 (2002).
   PubMed Web of Science ®Google Scholar
• Cozad SC, Townsend P, Morantz RA et al. Gliomatosis cerebri. Results with radiation therapy. Cancer78(8), 1789–1793 (1996).
   PubMed Web of Science ®Google Scholar
• Lodi R, Setola E, Tonon C et al. Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. Magn. Reson. Imaging21(9), 1003–1007 (2003).
   PubMed Web of Science ®Google Scholar
• Benjelloun A, Delavelle J, Lazeyras F, Dietrich PY. Possible efficacy of temozolomide in a patient with gliomatosis cerebri. Neurology57(10), 1932–1933 (2001).
   PubMed Web of Science ®Google Scholar
• Levin N, Gomori JM, Siegal T. Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. Neurology63(2), 354–356 (2004).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst.90(19), 1473–1479 (1998).
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner JC, Novotny P et al. Efficacy of neuroradiological imaging, neurological examination, and symptom status in follow-up assessment of patients with high-grade gliomas. J. Neurosurg.93(2), 201–207 (2000).
   PubMed Web of Science ®Google Scholar
• Stark AM, Nabavi A, Mehdorn HM, Blomer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg. Neurol.63(2), 162–169; discussion 169 (2005).
   PubMed Web of Science ®Google Scholar
• Yuile P, Dent O, Cook R, Biggs M, Little N. Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables. J. Clin. Neurosci.13(7), 747–751 (2006).
   PubMed Web of Science ®Google Scholar
• Krex D, Klink B, Hartmann C et al. Long-term survival with glioblastoma multiforme. Brain130(Pt 10), 2596–2606 (2007).
   PubMed Web of Science ®Google Scholar
• Inskip PD, Tarone RE, Brenner AV et al. Handedness and risk of brain tumors in adults. Cancer Epidemiol. Biomarkers Prev.12(3), 223–225 (2003).
   PubMed Web of Science ®Google Scholar